{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:56:39Z","timestamp":1793055399931,"version":"4.5.0"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,11,28]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Optimal strategies for increasing cervical cancer screening may differ by patient screening history and health care setting. Mailing human papillomavirus (HPV) self-sampling kits to individuals who are overdue for screening increases adherence; however, offering self-sampling kits to screening-adherent individuals has not been evaluated in the US.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the effectiveness of direct-mail and opt-in approaches for offering HPV self-sampling kits to individuals by cervical cancer screening history (screening-adherent and currently due, overdue, or unknown).<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>Randomized clinical trial conducted in Kaiser Permanente Washington, a US integrated health care delivery system. Individuals aged 30 to 64 years with female sex, a primary care clinician, and no hysterectomy were identified through electronic health records (EHRs) and enrolled between November 20, 2020, and January 28, 2022, with follow-up through July 29, 2022.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>Individuals stratified as due (eg, at the time of randomization, these individuals have been previously screened and are due for their next screening in \u22643 months) were randomized to receive usual care (patient reminders and clinician EHR alerts [n\u2009=\u20093671]), education (usual care plus educational materials about screening [n\u2009=\u20093960]), direct mail (usual care plus educational materials and a mailed self-sampling kit [n\u2009=\u20091482]), or to opt in (usual care plus educational materials and the option to request a kit [n\u2009=\u20093956]). Individuals who were overdue for screening were randomized to receive usual care (n\u2009=\u20095488), education (n\u2009=\u20091408), or direct mail (n\u2009=\u20091415). Individuals with unknown history for screening were randomized to receive usual care (n\u2009=\u20092983), education (n\u2009=\u20093486), or to opt in (n\u2009=\u20093506).<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary outcome was screening completion within 6 months. Primary analyses compared direct-mail or opt-in participants with individuals randomized to the education group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The intention-to-treat analyses included 31\u202f355 randomized individuals (mean [SD] age, 45.9 [10.4] years). Among those who were due for screening, compared with receiving education alone (1885 [47.6%]), screening completion was 14.1% (95% CI, 11.2%-16.9%) higher in the direct-mail group (914 [61.7%]) and 3.5% (95% CI, 1.2%-5.7%) higher in the opt-in group (2020 [51.1%]). Among individuals who were overdue, screening completion was 16.9% (95% CI, 13.8%-20.0%) higher in the direct-mail group (505 [35.7%]) compared with education alone (264 [18.8%]). Among those with unknown history, screening was 2.2% (95% CI, 0.5%-3.9%) higher in the opt-in group (634 [18.1%]) compared with education alone (555 [15.9%]).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>Within a US health care system, direct-mail self-sampling increased cervical cancer screening by more than 14% in individuals who were due or overdue for cervical cancer screening. The opt-in approach minimally increased screening. To increase screening adherence, systems implementing HPV self-sampling should prioritize direct-mail outreach for individuals who are due or overdue for screening. For individuals with unknown screening history, testing alternative outreach approaches and additional efforts to document screening history are warranted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04679675\">NCT04679675<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jama.2023.21471","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T16:01:53Z","timestamp":1701187313000},"page":"1971","source":"Crossref","is-referenced-by-count":61,"title":["Strategies to Increase Cervical Cancer Screening With Mailed Human Papillomavirus Self-Sampling Kits"],"prefix":"10.1001","volume":"330","author":[{"given":"Rachel L.","family":"Winer","sequence":"first","affiliation":[{"name":"Department of Epidemiology, University of Washington, Seattle"},{"name":"Kaiser Permanente Washington Health Research Institute, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa L.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Washington Health Research Institute, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin A.","family":"Tiro","sequence":"additional","affiliation":[{"name":"Biological Sciences Division, Department of Public Health Sciences, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly B.","family":"Green","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Washington Health Research Institute, Seattle"},{"name":"Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyuan","family":"Gao","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Washington Health Research Institute, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Meenan","sequence":"additional","affiliation":[{"name":"Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Hansen","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Washington Health Research Institute, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Sparks","sequence":"additional","affiliation":[{"name":"Washington Permanente Medical Group, Seattle"},{"name":"UnitedHealthcare Community Plan of Washington, SeaTac"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana S. M.","family":"Buist","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of Washington, Seattle"},{"name":"GRAIL LLC, Menlo Park, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9","key":"joi230128r1","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1093\/jnci\/dji115","article-title":"Cervical cancer in women with comprehensive health care access: attributable factors in the screening process.","volume":"97","author":"Leyden","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"joi230128r3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1006\/gyno.1998.5135","article-title":"Missed opportunities for cervical cancer screening of HMO members developing invasive cervical cancer (ICC).","volume":"71","author":"Kinney","year":"1998","journal-title":"Gynecol Oncol"},{"issue":"6","key":"joi230128r4","doi-asserted-by":"publisher","first-page":"791","DOI":"10.2105\/AJPH.85.6.791","article-title":"The screening histories of women with invasive cervical cancer, Connecticut.","volume":"85","author":"Janerich","year":"1995","journal-title":"Am J Public Health"},{"issue":"1","key":"joi230128r5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.43582","article-title":"Assessment of US Preventive Services Task Force Guideline-concordant cervical cancer screening rates and reasons for underscreening by age, race and ethnicity, sexual orientation, rurality, and insurance, 2005 to 2019.","volume":"5","author":"Suk","year":"2022","journal-title":"JAMA Netw Open"},{"key":"joi230128r6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2021.106596","article-title":"Impact of COVID-19 on cervical cancer screening: challenges and opportunities to improving resilience and reduce disparities.","volume":"151","author":"Wentzensen","year":"2021","journal-title":"Prev Med"},{"issue":"5","key":"joi230128r7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3322\/caac.v70.5","article-title":"Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society.","volume":"70","author":"Fontham","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"joi230128r8","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1001\/jama.2018.10897","article-title":"Screening for cervical cancer: US Preventive Services Task Force Recommendation Statement.","volume":"320","author":"Curry","year":"2018","journal-title":"JAMA"},{"key":"joi230128r9","doi-asserted-by":"publisher","first-page":"k4823","DOI":"10.1136\/bmj.k4823","article-title":"Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses.","volume":"363","author":"Arbyn","year":"2018","journal-title":"BMJ"},{"issue":"2","key":"joi230128r10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S1470-2045(18)30763-0","article-title":"Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial.","volume":"20","author":"Polman","year":"2019","journal-title":"Lancet Oncol"},{"key":"joi230128r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2020.104375","article-title":"Analytical performance of HPV assays on vaginal self-collected vs practitioner-collected cervical samples: the SCoPE study.","volume":"127","author":"Saville","year":"2020","journal-title":"J Clin Virol"},{"issue":"3","key":"joi230128r12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/BF02895117","article-title":"Barriers to mammography and Pap smear screening among women who recently had neither, one, or both types of screening.","volume":"22","author":"Glasgow","year":"2000","journal-title":"Ann Behav Med"},{"issue":"6","key":"joi230128r13","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1006\/pmed.2001.0844","article-title":"Reasons women do not attend screening for cervical cancer: a population-based study in Sweden.","volume":"32","author":"Eaker","year":"2001","journal-title":"Prev Med"},{"issue":"4","key":"joi230128r14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1258\/jms.2009.009073","article-title":"Barriers to cervical cancer screening attendance in England: a population-based survey.","volume":"16","author":"Waller","year":"2009","journal-title":"J Med Screen"},{"issue":"11","key":"joi230128r15","first-page":"745","article-title":"Implementation of systems strategies for breast and cervical cancer screening services in health maintenance organizations.","volume":"9","author":"Goins","year":"2003","journal-title":"Am J Manag Care"},{"key":"joi230128r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2021.106900","article-title":"Worldwide use of HPV self-sampling for cervical cancer screening.","volume":"154","author":"Serrano","year":"2022","journal-title":"Prev Med"},{"key":"joi230128r17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.cct.2017.11.004","article-title":"Rationale and design of the HOME trial: a pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake and effectiveness in a US healthcare system.","volume":"64","author":"Winer","year":"2018","journal-title":"Contemp Clin Trials"},{"issue":"11","key":"joi230128r18","doi-asserted-by":"publisher","first-page":"e1914729","DOI":"10.1001\/jamanetworkopen.2019.14729","article-title":"Effect of mailed human papillomavirus test kits vs usual care reminders on cervical cancer screening uptake, precancer detection, and treatment: a randomized clinical trial.","volume":"2","author":"Winer","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"11","key":"joi230128r19","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.44343","article-title":"Effect of patient characteristics on uptake of screening using a mailed human papillomavirus self-sampling kit: a secondary analysis of a randomized clinical trial.","volume":"5","author":"Winer","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"3","key":"joi230128r20","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1089\/jwh.2018.7070","article-title":"Understanding patients\u2019 perspectives and information needs following a positive home human papillomavirus self-sampling kit result.","volume":"28","author":"Tiro","year":"2019","journal-title":"J Womens Health (Larchmt)"},{"issue":"3","key":"joi230128r21","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1177\/0969141319885994","article-title":"Reactions of women underscreened for cervical cancer who received unsolicited human papillomavirus self-sampling kits.","volume":"27","author":"Malone","year":"2020","journal-title":"J Med Screen"},{"issue":"5","key":"joi230128r22","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/s41416-022-02094-w","article-title":"Offering HPV self-sampling kits: an updated meta-analysis of the effectiveness of strategies to increase participation in cervical cancer screening.","volume":"128","author":"Costa","year":"2023","journal-title":"Br J Cancer"},{"key":"joi230128r23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ypmed.2018.08.027","article-title":"Reducing overuse of cervical cancer screening: a systematic review.","volume":"116","author":"Alber","year":"2018","journal-title":"Prev Med"},{"key":"joi230128r24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2022.106960","article-title":"Design of a pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake in a US healthcare system: the STEP trial.","author":"Winer","journal-title":"Contemp Clin Trials"},{"key":"joi230128r25","doi-asserted-by":"publisher","first-page":"h2147","DOI":"10.1136\/bmj.h2147","article-title":"The PRECIS-2 tool: designing trials that are fit for purpose.","volume":"350","author":"Loudon","year":"2015","journal-title":"BMJ"},{"issue":"2","key":"joi230128r26","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/LGT.0000000000000528","article-title":"2019 ASCCP risk-based management consensus guidelines: methods for risk estimation, recommended management, and validation.","volume":"24","author":"Cheung","year":"2020","journal-title":"J Low Genit Tract Dis"},{"issue":"6","key":"joi230128r28","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"joi230128r29","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1037\/0033-2909.115.1.153","article-title":"A controlled, powerful multiple-comparison strategy for several situations.","volume":"115","author":"Levin","year":"1994","journal-title":"Psychol Bull"},{"key":"joi230128r32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2022.107307","article-title":"Factors associated with timely colposcopy following an abnormal cervical cancer test result.","volume":"164","author":"Feldman","year":"2022","journal-title":"Prev Med"},{"issue":"10","key":"joi230128r33","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1038\/s41416-022-01954-9","article-title":"HPV self-sampling among long-term non-attenders to cervical cancer screening in Norway: a pragmatic randomised controlled trial.","volume":"127","author":"Aasb\u00f8","year":"2022","journal-title":"Br J Cancer"},{"key":"joi230128r2","unstructured":"Centers for Disease Control and Prevention. Cancers associated with human papillomavirus, United States\u20142012\u20132016. Published May 4, 2022. Accessed November 5, 2023.? https:\/\/www.cdc.gov\/cancer\/uscs\/about\/data-briefs\/no10-hpv-assoc-cancers-UnitedStates-2012-2016.htm"},{"key":"joi230128r27","unstructured":"Centers for Disease Control and Prevention; Agency for Toxic Substances and Disease Registry; Geospatial Research, Analysis, and Services Program. CDC\/ATSDR social vulnerability index 2020 database US. Published January 24, 2023. Accessed November 5, 2023.? https:\/\/www.atsdr.cdc.gov\/placeandhealth\/svi\/data_documentation_download.html"},{"key":"joi230128r30","unstructured":"StataCorp. Stata Statistical Software: Release 15. Published online 2017. Accessed November 5, 2023.? https:\/\/www.stata-press.com\/data\/r15\/"},{"key":"joi230128r31","unstructured":"National Committee for Quality Assurance. HEDIS and Performance Measurement. Accessed November 5, 2023. https:\/\/www.ncqa.org\/hedis\/measures\/"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2812323\/jama_winer_2023_oi_230128_1700158787.25616.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T16:01:57Z","timestamp":1701187317000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2812323"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,11,28]]},"references-count":33,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2023,11,28]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2023.21471","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,28]]}}}